The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-positive metastatic breast cancer

This review article takes a deep dive into mechanisms of the three irreversible tyrosine kinase inhibitors (TKIs) currently approved for the treatment of HER2-positive metastatic breast cancer—pyrotinib, neratinib, and afatinib—as well as key clinical trials of irreversible TKIs plus chemotherapy compared with reversible TKIs/chemotherapy and other regimens.